Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide

Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide - Neoadjuvant dose-dense chemotherapy for HER2 negative breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019787

Enrollment

Registered

2016-01-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 negative primary breast cancer

Interventions

Nab Paclitaxel 4 cycleq2w (260 mg/m2) followed by EC 4 cycle q2w (Epirubicin 90mg/m2) (Cyclophosphamide 600mg/m2)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Conferm histology of invasive ductal carcinoma, HER2 negative status 2) Age 20>= 75<= 3) Performance status ECOG scale 0-1 4) No pvevious treatment of present breast cancer

Exclusion criteria

Exclusion criteria: 1) HER2 positivity 2) Previous incident of severe complication 3) Previous incident of institutional pneumonia 4) Previous incident of drug allergy 5) Active status of other cancers 6) Inflammatory breast cancer 7) Possible pregnancy

Design outcomes

Primary

Measure	Time frame
pCR rate	—

Secondary

Measure	Time frame
Histological response rate, breast consercing surgery rate, adverse event, DFS, OS	—

Countries

Japan

Contacts

Public ContactShigeto Ueda

International medical Center, Saitama Medical University Dept of breast oncology

syueda@saitama-med..ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026